HTML Preview Clinical Research Report Synopsis page number 1.
Janssen Research & Development
Clinical Research Report Synopsis
[GAL-USA-3; Phase III]
JNJ-17335630-AAD (Galantamine)
Redaction and Removal of Information in This Document
Information (including individual data listings, where applicable) has been removed or
redacted to protect the privacy of patients, study subjects, and all named persons associated
with the study. Names of companies other than Janssen Research & Development or
Johnson & Johnson affiliates have been redacted, unless a contractual agreement is in place
with those companies to disclose their names.
Information has been removed or redacted to protect commercially confidential information.
Aggregate data have been included, with any direct reference to an individual patient or
study subject excluded.
To disclose as much scientifically useful data as possible, no information other than that
outlined above has been removed or redacted.
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged
or confidential.